A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against B. anthracis Spores and Toxin

Anthrax vaccines primarily relying only on protective antigen (PA), the cell binding component in anthrax toxins provide incomplete protection when challenged with spores of virulent encapsulated strains. Alternatively, formaldehyde inactivated spores (FIS) or recombinant spore components generate a...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 10; p. 498
Main Authors Majumder, Saugata, Das, Shreya, Somani, Vikas Kumar, Makam, Shivakiran S, Kingston, Joseph J, Bhatnagar, Rakesh
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 19.03.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Anthrax vaccines primarily relying only on protective antigen (PA), the cell binding component in anthrax toxins provide incomplete protection when challenged with spores of virulent encapsulated strains. Alternatively, formaldehyde inactivated spores (FIS) or recombinant spore components generate anti-spore immune responses that inhibit the early stages of infection and augment the PA protective efficacy. In the present study domain IV of PA was spliced with exosporium antigen BxpB via a flexible G4S linker to generate a single functional antigen r-PAbxpB that was further assessed for its protective efficacy against anthrax toxins and spore infection. Immunization of mice with r-PAbxpB elicited significantly high titer antibodies comprising IgG1:IgG2a isotypes in 1:1 ratio, balanced up-regulation of both Th1 (IL2, IL12, IFN-γ) and Th2 (IL4, IL5, IL10) cytokines and high frequencies of CD4+ and CD8+ T cell subsets. The anti-r-PAbxpB antibodies significantly enhanced spore phagocytosis, and killing within macrophages; inhibited their germination to vegetative cells and completely neutralized the anthrax toxins as evidenced by the 100% protection in passive transfer studies. Active immunization with r-PAbxpB provided 100 and 83.3% protection in mice I.P. challenged with 5 × LD LD of toxins and 5 × 10 cfu/ml Ames spores, respectively while the sham immunized group succumbed to infection in 48 h. Therefore, the ability of r-PAbxpB to generate protective immune responses against both spores and toxin and provide significant protection suggests it as an efficient vaccine candidate against infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Carole Henry, University of Chicago, United States; Joel Bozue, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), United States; Wolfgang Beyer, University of Hohenheim, Germany; Okechukwu Chinazo Ndumnego, Africa Health Research Institute, South Africa
Edited by: Fabio Bagnoli, GlaxoSmithKline, Italy
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2019.00498